Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Immune Response to Sars-Covid-19 Vaccines in Haematological Patients: Prospective Single Center Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated EC-approved informed consent~* Hematological disease defined according to World Health Organization (WHO) criteria~* Female or male, 18 years of age or older~* ECOG performance status 0-3~* Willingness and ability to comply with routine clinical practice and study procedures~* Regular vaccination against SARS-CoV-2 according to Italian Haematological Society (SIE) guidelines/recommendations (Version 2.0, 20 April, 2021).~* Routine blood test planned between 30 and 60 days after administration of the second vaccine dose according to regular hematological follow up.~* Routine blood test planned no later than 9 months after the completion of the vaccination series (only in case of absence of circulation specific antibodies).~Exclusion Criteria:~* Preventive vaccination against SARS-CoV-2 not administered according to Italian Haematological Society (SIE) guidelines/recommendations (Version 2.0, 20 April, 2021)~* Evidence of previous infection with the SARS-Cov-2 virus.~* Routine blood test not planned between 30 and 60 days after administration of the second vaccine dose.~* Routine blood test not planned within 9 months after the completion of the vaccination series (only in case of absence of circulation specific antibodies).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).